DK166654B1 - THE CONTACT LENS CLEANING SITE WITH TWO TREATMENTS - Google Patents
THE CONTACT LENS CLEANING SITE WITH TWO TREATMENTS Download PDFInfo
- Publication number
- DK166654B1 DK166654B1 DK431286A DK431286A DK166654B1 DK 166654 B1 DK166654 B1 DK 166654B1 DK 431286 A DK431286 A DK 431286A DK 431286 A DK431286 A DK 431286A DK 166654 B1 DK166654 B1 DK 166654B1
- Authority
- DK
- Denmark
- Prior art keywords
- contact lens
- kit according
- lens cleaning
- cleaning kit
- enzyme catalyst
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/12—Non-macromolecular oxygen-containing compounds, e.g. hydrogen peroxide or ozone
- A61L12/124—Hydrogen peroxide; Peroxy compounds
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/0005—Other compounding ingredients characterised by their effect
- C11D3/0078—Compositions for cleaning contact lenses, spectacles or lenses
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Eyeglasses (AREA)
- Catalysts (AREA)
Description
DK 166654 B1DK 166654 B1
Opfindelsen angår et kontaktlinserensesæt med to hehandlings-midler, hvoraf det ene er et steriliserende hydrogenperoxid, og det andet er et enzymkatalysatorholdigt neutralisationsmiddel til neutralisation og sønderdeling af hydrogenper-5 oxidet efter sterilisationen af en kontaktlinse.The invention relates to a contact lens cleaning kit with two treatment agents, one of which is a sterilizing hydrogen peroxide and the other an enzyme catalyst-containing neutralizing agent for neutralizing and decomposing the hydrogen peroxide after sterilizing a contact lens.
Rensesæt til bløde og hårde kontaktlinser tjener til rensning og desinfektion samt til stabilisering af de optiske egenskaber og til forbedring af brugerens bekvemmelighed. Hydr-10 ogenperoxid er som antimikrobielt stof blevet vigtigt til desinfektion og rensning af kontaktlinser. Sammenlignet med chlorhexidinsalte eller organimercuroforbindelser såsom thiomersal, som også benyttes til desinfektion af kontaktlinser, har hydrogenperoxid bedre antimikrobiel effekt, 15 især over for de forholdsvis resistente Aspergillus-arter.Cleansing kits for soft and hard contact lenses serve to cleanse and disinfect, as well as to stabilize the optical properties and to enhance user convenience. Hydr-10 ogen peroxide has become important as an antimicrobial agent for disinfecting and cleaning contact lenses. Compared to chlorhexidine salts or organo-mercury compounds such as thiomersal, which are also used to disinfect contact lenses, hydrogen peroxide has better antimicrobial effect, especially in the relatively resistant Aspergillus species.
De kendte hydrogenperoxidopløsninger, der benyttes til rensning af kontaktlinser, er 3%'s peroxidopløsninger (tysk patentskrift nr. 2.425.714). Efter behandling af kontaktlinserne med disse opløsninger, hæfter forholdsvis store 20 restmængder af hydrogenperoxidopløsning til linserne. Når de således behandlede linser anbringes på øjet, fører disse restmængder til forskellige grader af irritation af øjets slimhinde. Derfor er det efter behandling med hydrogenperoxidopløsning nødvendigt at behandle linserne med en neutra-25 liserende opløsning, ved hvis hjælp hydrogenperoxidet spaltes i vand og oxygen. Elimineringen efter sterilisation af restmængder af hydrogenperoxid ved sønderdeling ved hjælp af især tungmetalkatalysatorer kendes fra ovennævnte tyske patentskrift. Det er her nødvendigt at bruge to forskellige 30 behandlingstrin, nemlig først en sterilisering af linsen og derefter en eliminering af resthydrogenperoxidet i et vandigt system, som indeholder katalysatoren. Håndteringen af linserne og desinfektionen og rensningen er derfor forholdsvis kompliceret. Valget af passende katalysatorer, som benyttes 35 til sønderdelingen af restmængderne af hydrogenperoxid, frembyder også vanskeligheder.The known hydrogen peroxide solutions used to purify contact lenses are 3% peroxide solutions (German Patent No. 2,425,714). After treating the contact lenses with these solutions, relatively large residual amounts of hydrogen peroxide solution are adhered to the lenses. When the lenses thus treated are applied to the eye, these residual amounts lead to varying degrees of irritation of the eye's mucosa. Therefore, after treatment with hydrogen peroxide solution, it is necessary to treat the lenses with a neutralizing solution by which the hydrogen peroxide is decomposed into water and oxygen. The elimination after sterilization of residual amounts of hydrogen peroxide by decomposition by means of especially heavy metal catalysts is known from the above mentioned German patent. Here it is necessary to use two different processing steps, namely first sterilization of the lens and then elimination of the residual hydrogen peroxide in an aqueous system containing the catalyst. The handling of the lenses and the disinfection and cleansing is therefore relatively complicated. The choice of suitable catalysts used for the decomposition of the residual amounts of hydrogen peroxide also presents difficulties.
2 DK 166654 B12 DK 166654 B1
Som katalysatorer til sønderdeling af hydrogenperoxidet efter brug er det kendt at anvende enzymatiske peroxidaser, især catalase fra EP-A-82 798. Også i dette tilfælde hældes hydrogenperoxidopløsningen imidlertid bort efter desinfek-5 tionsbehandlingen, hvorpå den erstattes med en neutraliserende opløsning, som indeholder den peroxidneutraliserende katalysator, f.eks. peroxidase. Også her kræves der derfor to på hinanden følgende behandlingstrin, hvilket gør ren-seoperationen forholdsvis kompliceret.As catalysts for decomposing the hydrogen peroxide after use, it is known to use enzymatic peroxidases, in particular catalase from EP-A-82 798. However, in this case, however, the hydrogen peroxide solution is poured after the disinfection treatment and replaced with a neutralizing solution containing the peroxide neutralizing catalyst, e.g. peroxidase. Here, too, two consecutive treatment steps are required, which makes the cleaning operation relatively complicated.
10 I begge tilfælde er det umuligt at behandle en kontaktlinse under samtidig brug af hydrogenperoxid og en neutraliserende opløsning med en sønderdelingskatalysator, fordi hydrogenperoxidet i så fald sønderdeles til oxygen og vand ved hjælp 15 af den neutraliserende opløsning med sønderdelingskatalysatoren, før den har udøvet en tilstrækkelig steriliserende virkning til eliminering af alle kim på linserne, hvilket kræver 1-4 timer, især i tilfælde af bløde linser.In both cases, it is impossible to treat a contact lens while using hydrogen peroxide and a neutralizing solution with a decomposition catalyst, because then the hydrogen peroxide is decomposed to oxygen and water by the neutralizing solution with the decomposition catalyst before it has sufficient sterilizing effect to eliminate all germs on the lenses, requiring 1-4 hours, especially in the case of soft lenses.
20 Fra EP patentskrift nr. 139.994 kendes et kontaktlinseren-sesæt, hvori der anvendes hydrogenperoxid og tillige en tablet, som indeholder en forbindelse, der kan neutralisere hydrogenperoxid, og som er forsynet med et overtræk, der først opløses efter en vis tid. Som hydrogenperoxidneutra-25 liserende forbindelse anvendes forbindelser, som efter neutralisering af hydrogenperoxidet medvirker til dannelse af en pufret linseopbevaringsopløsning, og som følgelig er ionforbindelser. Det anføres endvidere i EP patentskrift nr. 139.994, at anvendelse af neutraliserende forbindelser, 30 der virker katalytisk, f.eks. peroxidase/catalase-enzym dels er kostbar, dels ikke medvirker til dannelse af en pufret linseopbevaringsopløsning. EP patentskrift nr. 139.994 repræsenterer således en fordom mod anvendelse af enzymkatalysatorer i kontaktlinserensesæt.20 EP patent specification No. 139,994 discloses a contact lens sensing kit which utilizes hydrogen peroxide and also a tablet containing a compound which can neutralize hydrogen peroxide and which is provided with a coating which dissolves only after a certain time. As the hydrogen peroxide neutralizing compound are used compounds which, after neutralizing the hydrogen peroxide, contribute to the formation of a buffered lens storage solution and are consequently ionic compounds. It is further stated in EP Patent No. 139,994 that the use of catalytic neutralizing compounds, e.g. peroxidase / catalase enzyme is partly expensive and partly does not contribute to the formation of a buffered lens storage solution. Thus, EP Patent No. 139,994 represents a prejudice against the use of enzyme catalysts in contact lens cleaning kits.
35 3 DK 166654 B135 3 DK 166654 B1
Formålet med opfindelsen er at anvise et rensesæt til kontaktlinser, som i et eneste trin holder hydrogenperoxid i aktiv form i tilstrækkelig lang tid til sterilisering af linserne, og som derefter neutraliserer restmængden af hydr-5 ogenperoxid på linserne, så at linserne derefter kan bæres uden ulemper.The object of the invention is to provide a contact lens cleaning kit which in a single step holds hydrogen peroxide in active form for a sufficient period of time to sterilize the lenses and which then neutralizes the residual amount of hydrogen and peroxide on the lenses so that the lenses can then be worn without disadvantages.
Dette formål opnås med det i kravene angivne kontaktlinse-rensesæt, og man overvinder den førnævnte fordom.This object is achieved with the contact lens cleaning kit set forth in the claims and the aforementioned prejudice is overcome.
1010
Til dette formål anviser opfindelsen et rensesæt til kontaktlinser med to behandlingsmidler: nemlig hydrogenperoxid og et neutralisationsmiddel indeholdende en enzymkatalysator. Hydrogenperoxidet er tilstrækkeligt til sterilisation af en 15 hård eller blød kontaktlinse eller begge dele. Neutralisationsmidlet er tilstrækkeligt til sønderdeling af enhver restmængde af hydrogenperoxidet på linserne til oxygen og vand, efter at hydrogenperoxidet har steriliseret linserne, så at disse kan bæres uden ulempe. Neutralisationsmidlet 20 indeholder en enzymkatalysator og et neutralisationsmiddel til sønderdeling af restmængden af hydrogenperoxid og er kombineret med et forsinkelsesmiddel. Forsinkelsesmidlet udsætter tidspunktet for frigivelsen af neutralisationsmidlet, til hydrogenperoxidet har steriliseret linserne.To this end, the invention provides a contact lens cleaning kit with two treatment agents: namely hydrogen peroxide and a neutralizing agent containing an enzyme catalyst. The hydrogen peroxide is sufficient to sterilize a hard or soft contact lens or both. The neutralizing agent is sufficient to decompose any residual amount of the hydrogen peroxide on the oxygen and water lenses after the hydrogen peroxide has sterilized the lenses so that they can be worn without disadvantage. The neutralizing agent 20 contains an enzyme catalyst and a neutralizing agent to decompose the residual amount of hydrogen peroxide and is combined with a delay agent. The delay agent delays the time of release of the neutralizing agent until the hydrogen peroxide has sterilized the lenses.
25 I overensstemmelse hermed er kontaktlinserensesættet ifølge opfindelsen ejendommeligt ved, at neutralisationsmidlet og/eller enzymkatalysatoren, som sønderdeler hydrogenperoxidet, er kombineret med et forsinkelsesmiddel, som regu-30 lerer den forsinkede frigivelse.Accordingly, the contact lens cleaning kit of the invention is peculiar in that the neutralizing agent and / or enzyme catalyst which decomposes the hydrogen peroxide is combined with a delay agent which regulates the delayed release.
Gennem opfindelsen lettes derfor resningen af kontaktlinserne, som kan være hårde eller bløde, fordi der kun kræves et enkelt trin. Linserne og neutralisationsmidlet med enzym-35 katalysatoren og forsinkelsesmidlet anbringes i en steriliserende opløsning af hydrogenperoxid. Forsinkelsesmidlet, 4 DK 166654 B1 som kommer i kontakt med hydrogenperoxidet under neddypnin-gen, frigiver da i det mindste en neutraliserende mængde af det enzymkatalysatorholdige neutralisationsmiddel, efter at hydrogenperoxidet har virket på kontaktlinserne i tilstræk-5 kelig tid til sterilisation.The invention therefore facilitates the erection of the contact lenses, which may be hard or soft because only a single step is required. The lenses and the neutralizing agent with the enzyme catalyst and the delaying agent are placed in a sterilizing solution of hydrogen peroxide. The delay agent, 4 contacting the hydrogen peroxide during the immersion, then releases at least a neutralizing amount of the enzyme catalyst-containing neutralizing agent after the hydrogen peroxide has acted on the contact lenses for a sufficient time for sterilization.
Til dette formål kan neutralisationsmidlet være overtrukket med forsinkelsesmidlet til neddypning i en vandig hydrogenpe-roxidopløsning sammen med linserne. Den forsinkede afgivelse 10 kan indstilles, især i indtil fire timer, ved hjælp af tykkelsen af det overtræk, som opløses i hydrogenperoxidopløs-ningen. Som følge af frigørelsen af det enzymkatalysatorholdige neutralisationsmiddel ved overtrækkets opløsning virker neutralisationsmidlet automatisk uden yderligere 15 indgreb fra brugerens side. Hydrogenperoxidopløsningen er sur (med en pH-værdi under 4) i den stabile tilstand til opnåelse af både sterilisation og opløsning. Enzymkatalysatoren, som befinder sig inde i overtrækket, sønderdeler derpå den steriliserende hydrogenperoxidopløsning i en be-20 handlingsbeholder, hvori linserne og neutralisationsmidlet er blevet anbragt på samme tid.For this purpose, the neutralizing agent may be coated with the delay agent for immersion in an aqueous hydrogen peroxide solution together with the lenses. The delayed release 10 can be adjusted, especially for up to four hours, by the thickness of the coating dissolved in the hydrogen peroxide solution. As a result of the release of the enzyme catalyst-containing neutralizing agent by the coating solution, the neutralizing agent operates automatically without further user intervention. The hydrogen peroxide solution is acidic (with a pH below 4) in the stable state to obtain both sterilization and solution. The enzyme catalyst located within the coating then decomposes the sterilizing hydrogen peroxide solution into a treatment vessel in which the lenses and the neutralizing agent have been placed at the same time.
Eksempler på sammensætningen af hydrogenperoxidopløsningen og af det enzymkatalysatorholdige neutralisationsmiddel er 25 angivet i tysk offentliggørelsesskrift nr. 3.410.400.Examples of the composition of the hydrogen peroxide solution and of the enzyme catalyst-containing neutralizing agent are given in German Publication No. 3,410,400.
Endvidere er følgende sammensætning egnet til neutralisationsmidlet:Furthermore, the following composition is suitable for the neutralizing agent:
0,05 vægtprocent catalasekoncentrat, 260.000 enheder/ml 30 0,05 vægtprocent hydroxypropylmethylcellulose USP XX0.05 wt% catalase concentrate, 260,000 units / ml 0.05 wt% hydroxypropyl methyl cellulose USP XX
0,05 vægtprocent NaH2P04, 2H20 DAB 8 0,25 vægtprocent Na2HP04, 2H20 0,75 vægtprocent natriumchlorid EP I0.05% by weight of NaH2PO4, 2H20 DAB 8 0.25% by weight Na2HPO4, 2H20 0.75% by weight sodium chloride EP I
35 I det følgende angives en yderligere hensigtsmæssig sammensætning af neutralisationsmidlet: 5 DK 166654 B1 3-12 mg passende pufferstof, f.eks. alkalimetalphosphat, -borat eller -citrat, glycin 40-70 mg neutral elektrolyt (f.eks. NaCl, KC1) 5-10 mg alkalimetalhydrogencarbonat 5 5-10 mg vandopløselig polymer, f.eks. polyvinylpyrrolidon 0,2-1 mg enzymkatalysator (catalase, peroxidase) pr. enkeltdosis.In the following, a further appropriate composition of the neutralizing agent is indicated: 3-12 mg of suitable buffer, e.g. alkali metal phosphate, borate or citrate, glycine 40-70 mg of neutral electrolyte (eg NaCl, KCl) 5-10 mg of alkali metal hydrogen carbonate 5-10 mg of water-soluble polymer, e.g. polyvinylpyrrolidone 0.2-1 mg enzyme catalyst (catalase, peroxidase) per single dose.
Denne mængde er tilstrækkelig til sønderdeling, til neutra-10 lisation og til regulering til en osmolaritet på 270-320 mosmol af 7 ml af en hydrogenperoxidopløsning. Disse 7 ml svarer til rumfanget af en standardkontaktlinsebeholder eller en kontaktlinsebehandlingsbeholder.This amount is sufficient for decomposition, for neutralization and for control to an osmolarity of 270-320 moles of 7 ml of a hydrogen peroxide solution. These 7 ml correspond to the volume of a standard contact lens container or contact lens treatment container.
15 Et eksempel på yderligere en særlig sammensætning af neutralisationsmidlet er som følger: 5,6 mg kaliumhydrogenphosphat 8 mg dinatriumhydrogenphosphat 52,4 mg NaCl 20 7 mg natriumhydrogencarbonat 4,8 mg polyvinylpyrrolidon K25 0,3 mg enzymkatalysatorAn example of a further particular composition of the neutralizing agent is as follows: 5.6 mg potassium hydrogen phosphate 8 mg disodium hydrogen phosphate 52.4 mg NaCl 20 7 mg sodium bicarbonate 4.8 mg polyvinylpyrrolidone K25 0.3 mg enzyme catalyst
Den ovenfor angivne sammensætning af neutralisationsmidlet 25 benyttes som kapselfyldning, idet kapslen er udformet som det forsinkelsesmiddel, som omgiver det enzymkatalysator-holdige neutralisationsmiddel. Kapslen omfatter en vandopløselig polymer, især en polyvinylalkohol.The above composition of the neutralizing agent 25 is used as capsule filling, the capsule being designed as the delay agent surrounding the enzyme catalyst-containing neutralizing agent. The capsule comprises a water-soluble polymer, especially a polyvinyl alcohol.
30 Neutralisationsmidlet kan også formes til en tablet, som forsynes med et vandopløseligt overtræk, som bevirker forsinket opløsning af tabletten. Det vandopløselige overtræk kan omfatte en polymer, som er opløselig i et surt medium, såsom en polymer af dimethylaminomethacrylat og neutrale 35 methacrylestere. Overtrækket kan også omfatte en pH-neutral opløselig polymer. Polymere, som egner sig til dette formål, DK 166654 Bl 6 er f.eks. opløselige celluloseethere såsom methylcellulose, methylhydroxypropylcellulose, methylhydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, natriumcarb-oxymethylcellulose, celluloseacetatphthalat, hydroxypropyl-5 methylcelluloseephthalat, polymere af methacrylsyre og meth-acrylatestere, et overtræk af en vandig dispersion af en copolymer af methacrylsyre og methacrylatestere, et overtræk af en vandig dispersion af celluloseacetatphthalat, copoly-mere af methylvinylether og maleinsyreanhydrid, og polyvin-10 ylalkoholer.The neutralizing agent may also be formed into a tablet which is provided with a water-soluble coating which causes delayed dissolution of the tablet. The water-soluble coating may comprise a polymer which is soluble in an acidic medium, such as a polymer of dimethylaminomethacrylate and neutral methacrylic esters. The coating may also comprise a pH-neutral soluble polymer. Polymers suitable for this purpose, e.g. soluble cellulose ethers such as methyl cellulose, methyl hydroxypropyl cellulose, methyl hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, sodium carboxymethyl cellulose, cellulose acetate phthalate, hydroxypropyl methyl acetate acetate, aqueous dispersion of cellulose acetate phthalate, copolymer of methyl vinyl ether and maleic anhydride, and polyvinyl yl alcohols.
Passende polyalkoholer, især i en mængde på 0,2-1 mg pr. tablet, kan sættes til disse polymere til regulering af forsinkelsen. Til dette formål er især 1,2-propylenglycol, 15 polyethylenglycoler og citratestere egnede.Suitable polyalcohols, especially in an amount of 0.2-1 mg per liter. tablet, can be added to these polymers to control the delay. For this purpose, especially 1,2-propylene glycol, 15 polyethylene glycols and citrate esters are suitable.
Overtrækket kan fremstilles ud fra den vandopløselige polymer under anvendelse af velkendte fremgangsmåder, f.eks. ved påsprøjtning af en film i en overtræksbeholder, ved fluidi-20 sering (Wurster-metode) eller i lukkede systemer. Den foretrukne mængde polymer til overtrækning af en tablet er 2,0- 5,0 mg.The coating may be prepared from the water-soluble polymer using well known methods, e.g. by spraying a film into a coating container, by fluidization (Wurster method) or in closed systems. The preferred amount of polymer for coating a tablet is 2.0 to 5.0 mg.
Nedenfor er der givet et eksempel på en tabletsammensætning, 25 som udgør det enzymkatalysatorholdige neutralisationsmiddel: 11,2 mg dinatriumhydrogenphosphat 55,8 mg NaCl 4,8 g polyvinylpyrrolidon K25 0,2 mg enzymkatalysator (catalase, peroxidase) 30Below is an example of a tablet composition 25 which is the enzyme catalyst-containing neutralizing agent: 11.2 mg disodium hydrogen phosphate 55.8 mg NaCl 4.8 g polyvinylpyrrolidone K25 0.2 mg enzyme catalyst (catalase, peroxidase) 30
Nedenfor er der anført et eksempel på en syreopløselig polymer, der egner sig som overtræk: 1,9 mg methacrylatester 0,4 mg hydroxypropylmethylcellulose 35 0,2 mg polyethylenglycol (1000) 7 DK 166654 B1 oBelow is an example of an acid-soluble polymer suitable as a coating: 1.9 mg methacrylate ester 0.4 mg hydroxypropylmethylcellulose 35 0.2 mg polyethylene glycol (1000) 7 DK 166654 B1 o
Nedenfor er der anført et eksempel på en overtræksfilm af en polymer, som er opløselig i neutralt miljø: 2.2 mg hydroxypropylmethylcellulosephthalat 5 0,3 mg polyethylenglycol (1000)Below is an example of a coating film of a polymer which is soluble in neutral environment: 2.2 mg hydroxypropylmethylcellulose phthalate 5 0.3 mg polyethylene glycol (1000)
Det er også muligt at forsegle et enzymkatalysatorholdigt neutralisationsmiddel, som er formet til en tablet, med en vandopløselig film af f.eks. polyvinylalkohol, som virker 10 som forsinkelsesmiddel. Blødgørere i form af polyvalente alkoholer og vand sættes i en mængde på 3,5%-5% til polyvinylalkohol filmen, hvorved der opnås en forsinket opløsning af filmen. Filmen kan have en tykkelse på 30-150 μπι. Gasper-meabiliteten (DIN 53 380) er 0,9-1,4 ml/m2/<Vkar· Filmene 15 kan svejses ved temperaturer på 140-190°C ved et kontakttryk på 4-5 bar.It is also possible to seal an enzyme catalyst-containing neutralizing agent formed into a tablet with a water-soluble film of e.g. polyvinyl alcohol which acts as a delay agent. Plasticizers in the form of polyhydric alcohols and water are added in an amount of 3.5% -5% to the polyvinyl alcohol film, whereby a delayed solution of the film is obtained. The film can have a thickness of 30-150 μπι. The gas permeability (DIN 53,380) is 0.9-1.4 ml / m2 / <Vkar · The films 15 can be welded at temperatures of 140-190 ° C at a contact pressure of 4-5 bar.
Det enzymkatalysatorholdige neutralisationsmiddel i form af en tablet kan også overtrækkes med en uopløselig, men dog 20 semipermeabel membran. Denne membran kan også påføres ved anvendelse af kendte overtræksmetoder såsom ved påsprøjtning, ved fluidisering eller i lukkede systemer i en mængde på 3-10 mg pr. tablet. Den semipermeable membran kan f.eks. dannes ud fra en organisk opløsning af ethylcellulose, en vandig 25 dispersion af ethylcellulose, en copolymer af acrylat/meth-acrylat-estere med trimethylammoniummethacrylat, en vandig dispersion af blandede methylmethacrylater og ethylmethacry 1 -ater. Til regulering af diffusionshastigheden kan der tilsættes passende blødgørere, især i en mængde på 1,5-5,0 mg 30 pr. tablet. Som blødgørere kan anvendes 1,2-propylenglycol, polyethylenglycoler og citratestere. Et eksempel på sammensætningen af en semipermeabel membran er som følger: 3,8 mg ethylcellulose N22 1.2 mg polyethylenglycol (6.000) 35The enzyme catalyst-containing neutralizing agent in the form of a tablet can also be coated with an insoluble, but 20 semipermeable membrane. This membrane can also be applied using known coating methods such as by spraying, by fluidization or in closed systems in an amount of 3-10 mg / ml. tablet. The semipermeable membrane can e.g. is formed from an organic solution of ethyl cellulose, an aqueous dispersion of ethyl cellulose, a copolymer of acrylate / methacrylate esters with trimethylammonium methacrylate, an aqueous dispersion of mixed methyl methacrylates and ethyl methacrylic 1-aates. To adjust the rate of diffusion, suitable plasticizers may be added, especially in an amount of 1.5-5.0 mg / ml. tablet. 1,2-propylene glycol, polyethylene glycols and citrate esters can be used as plasticizers. An example of the composition of a semi-permeable membrane is as follows: 3.8 mg ethylcellulose N22 1.2 mg polyethylene glycol (6,000) 35
Et yderligere eksempel på et forsinkelsesmiddel, ved hvis 8 DK 166654 B1 ΰ hjælp der kan opnås en forsinket afgivelse af enzymkataly-satoren, der sønderdeler hydrogenperoxidet, og af neutralisationsmidlet, er en kvældbar, men dog tungtopløselig eller uopløselig matrix, især i tabletform, hvori det enzymkata-5 lysatorholdige neutralisationsmiddel er fordelt. Det enzym-katalysatorholdige neutralisationsmiddel, der kan have en af ovenstående sammensætninger, indkorporeres i den omtalte matrix, som kan omfatte naturlig eller delvis syntetisk polymere. Den især tabletformede matrix kan fremstilles ved 10 konventionelle processer, f.eks. ved granulering og støbning af udgangsmaterialerne. Det er også muligt at forarbejde blandingen af udgangsmaterialer direkte til tabletter uden forudgående granulering. Polymere, som egner sig til dannelse af matrixen, er opløselige celluloseethere såsom de oven-15 nævnte, alkalimetalsalte af alginsyre, methacrylsyrederiva-ter, især acrylat/methacrylat-estere, acryl syrederivater, dextraner (molekylvægt 1.000-75.000) og polyvinylalkoholer. Nedenfor er der anført et eksempel på en matrix, hvori det enzymkatalysatorholdige neutralisationsmiddel er inkorpore-20 ret: 0,3 mg enzymkatalysator (catalase, peroxidase) 10,2 mg dinatriumhydrogenphosphat 55,8 mg NaCl 4,7 mg polyvinylpyrrolidon K25 25 15 mg hydroxypropylmethylcelluloseA further example of a delay agent by which a delayed release of the enzyme catalyst which decomposes the hydrogen peroxide and of the neutralizing agent can be obtained is a swellable, yet highly soluble or insoluble matrix, especially in tablet form, wherein the enzyme catalyst-containing neutralizing agent is distributed. The enzyme catalyst-containing neutralizing agent, which may have any of the above compositions, is incorporated into the aforementioned matrix which may comprise natural or partially synthetic polymer. The particularly tablet-shaped matrix can be prepared by 10 conventional processes, e.g. by granulating and casting the starting materials. It is also possible to process the mixture of starting materials directly into tablets without prior granulation. Polymers suitable for forming the matrix are soluble cellulose ethers such as the aforementioned alkali metal salts of alginic acid, methacrylic acid derivatives, especially acrylate / methacrylate esters, acrylic acid derivatives, dextrans (molecular weight 1,000-75,000) and polyvinyl alcohols. Below is an example of a matrix incorporating the enzyme catalyst-containing neutralizing agent: 0.3 mg of enzyme catalyst (catalase, peroxidase) 10.2 mg of disodium hydrogen phosphate 55.8 mg of NaCl 4.7 mg of polyvinylpyrrolidone K25 25 mg of hydroxypropyl methylcellulose
Der støbes tabletter med en vægt på f.eks. 86 mg og en diameter på 6 mm.Tablets with a weight of e.g. 86 mg and a diameter of 6 mm.
30 Det er også muligt at inkorporere enzymkatalysatoren og neutralisationsmidlet i en høj koncentreret vandig polymeropløsning, hvoraf der ved støbning og tørring kan fremstilles folier med en tykkelse på 1,0-3,0 mm. Ved opskæring af folien til den ønskede størrelse kan der fremstilles passende en-35 hedsdoser med forudberegnede overfladedimensioner. De vandopløselige polymere virker som forsinkelsesmidler, hvorved 9 DK 166654 B1 man opnår en forsinket afgivelse af enzymkatalysator og neutralisationsmiddel. Passende polymere er vandopløselige celluloseethere som ovennævnte, alkalimetalalginater, dex-traner og polyvinylalkoholer.It is also possible to incorporate the enzyme catalyst and the neutralizing agent into a highly concentrated aqueous polymer solution, from which foils having a thickness of 1.0-3.0 mm can be prepared. By cutting the film to the desired size, suitable unit doses with predetermined surface dimensions can be prepared. The water-soluble polymers act as delay agents, thereby providing a delayed release of enzyme catalyst and neutralizing agent. Suitable polymers are water-soluble cellulose ethers such as the above, alkali metal alginates, dextranes and polyvinyl alcohols.
55
Det er kendt ved indgiften af lægemidler at benytte terapeutiske systemer i form af tabletter, semipermeable membraner og matricer, som anbringes i bestemte målområder i et biosystem til opnåelse af en konstant afgivelse af lægemidlet 10 i løbet af et længere tidsrum. I modsætning til dette opnår man gennem den foreligende opfindelse, at den hydrogenper-oxidsønderdelende enzymkatalysator sammen med det steriliserende hydrogenperoxid kan benyttes på samme tid til behandling af kontaktlinser uden skadelig virkning fra enzym-15 katalysatoren på hydrogenperoxidets ønskede sterilisationsvirkning i en periode på f.eks. 4 timer. Enzymkatalysatorens sønderdelende virkning på hydrogenperoxidet starter først ved slutningen af den ønskede behandlingstid.It is known in the administration of drugs to use therapeutic systems in the form of tablets, semipermeable membranes and matrices placed in specific target areas of a biosystem to obtain a constant release of the drug 10 over a prolonged period of time. In contrast, the present invention provides that the hydrogen peroxide decomposing enzyme catalyst together with the sterilizing hydrogen peroxide can be used at the same time to treat contact lenses without detrimental effect from the enzyme catalyst on the desired sterilization effect of the hydrogen peroxide for a period of e.g. . 4 hours. The disintegrating effect of the enzyme catalyst on the hydrogen peroxide starts only at the end of the desired treatment time.
20 En forsinket afgivelse af enzymkatalysatoren kan også opnås ved immobilisering af enzymkatalysatoren på partikelformede bærestoffer, især acrylharpikspartikler, f.eks. ved binding ved hjælp af reaktionsdygtige oxirangrupper. Bærestofferne sammen med enzymkatalysatoren, som er immobiliseret derpå, 25 anbringes i passende mængde på f.eks. bunden eller låget af en kontaktlinsebehandlingsbeholder med gevind og adskilles fra behandlingsopløsningen, som indeholder de pH-neutrali-serende materialer og de neutrale salte sammen med hydrogenperoxidet, ved hjælp af permeable indifferente netformede 30 sier. I denne udformning er enzymkatalysatoren anbragt i den ene del af behandlingsbeholderen uden sammenblanding med behandlingsopløsningen. På denne måde undgås risikoen for, at enzymkatalysatormaterialet akkumuleres i de bløde linser under behandling af linserne. F.eks. kan en mængde 35 bærestof med immobiliseret enzymkatalysator til 30 dages brug. anbringes i beholderdelen.A delayed release of the enzyme catalyst can also be achieved by immobilizing the enzyme catalyst on particulate carriers, especially acrylic resin particles, e.g. by binding by reactive oxirane groups. The carriers, together with the enzyme catalyst immobilized thereon, are applied in an appropriate amount, e.g. the bottom or lid of a threaded contact lens treatment container and separated from the treatment solution containing the pH neutralizing materials and neutral salts together with the hydrogen peroxide by permeable inert mesh webs. In this embodiment, the enzyme catalyst is placed in one portion of the treatment vessel without mixing with the treatment solution. In this way, the risk of the enzyme catalyst material being accumulated in the soft lenses during treatment of the lenses is avoided. Eg. can use an amount of 35 carrier with immobilized enzyme catalyst for 30 days of use. placed in the container part.
DK 166654 B1 10DK 166654 B1 10
Behandlingsopløsningen, hvori frigivelsen af det enzymkata-lysatorholdige neutraliseringsmiddel finder sted, kan have en pH-værdi på 7-7,5, især 7,3 og en osmolaritet på ca. 300 5 mosmol.The treatment solution in which the release of the enzyme catalyst-containing neutralizing agent takes place may have a pH of 7-7.5, especially 7.3 and an osmolarity of approx. 300 5 mosmol.
Et farveskift, især ved brug af en farveindikator (pH/redox-indikator), som skifter farve ved en pH-værdi på 7,0-7,5 og især ved 7,3, fortæller brugeren, at hydrogenperoxidet, som 10 er brugt til sterilisationsbehandlingen, er blevet sønderdelt. Til dette formål egner sig navnlig højmolekylære farvestoffer, som ikke trænger ind i linsematerialet.A color change, especially when using a color indicator (pH / redox indicator) which changes color at a pH of 7.0-7.5 and especially at 7.3, tells the user that the hydrogen peroxide used is 10 for the sterilization treatment, has been disintegrated. For this purpose, in particular, high molecular colors which do not penetrate the lens material are suitable.
For at enzymkatalysatoren kun skal udøve sin virkning efter 15 desinfektion- og sterilisationsbehandlingen af linserne, kan dette enzymkatalysatoradditiv, som tillige med hjælpematerialerne er til stede i neutralisationsmidlet, og som tjener til neutralisation af hydrogenperoxid, forsynes med et overtræk, som sikrer at enzymkatalysatoren til sønderde-20 ling af hydrogenperoxidet kun frigøres efter den fornødne behandlingstid på indtil 4 timer. Der er mange muligheder til opnåelse af dette.In order for the enzyme catalyst to exert its effect only after the disinfection and sterilization treatment of the lenses, this enzyme catalyst additive, as well as the auxiliary materials present in the neutralizing agent, which serves to neutralize hydrogen peroxide, can be provided with a coating which ensures that the enzyme catalyst is used. -20 ling of the hydrogen peroxide is released only after the required treatment time of up to 4 hours. There are many ways to achieve this.
Overtrækket på enzymkatalysatoren og hjælpematerialerne kan 25 have form af en kapsel, som er vandopløselig ved den pH-værdi, hvor hydrogenperoxidopløsningen er stabil, dvs. ved en pH-værdi ved 4-5, og som ikke flokkuleres eller udfældes i neutral opløsning, dvs. ved en pH-værdi på 7,3.The coating on the enzyme catalyst and the auxiliary materials may take the form of a capsule which is water soluble at the pH at which the hydrogen peroxide solution is stable, i.e. at a pH value of 4-5 and which is not flocculated or precipitated in neutral solution, i.e. at a pH of 7.3.
30 Det er endvidere en fordel, at kapslen har en eller to eller eventuelt flere laserperforeringer, gennem hvilke hjælpematerialerne frigøres ved kontakt med hydrogenperoxidopløsningen, idet kapslen opløses helt, når en pH-værdi på ca. 7 er nået, med henblik på frigivelse af enzymkatalysatoren på 35 dette tidspunkt.It is further advantageous that the capsule has one or two or optionally several laser perforations through which the auxiliary materials are released upon contact with the hydrogen peroxide solution, the capsule dissolving completely when a pH of approx. 7 is reached for release of the enzyme catalyst at this time.
11 DK 166654 B111 DK 166654 B1
Enzymkatalysatoren kan også være til stede som enzymkorn eller -granulat (prill), som sammen med hjælpematerialerne fyldes i kapslen, som har de førnævnte opløselighedsegenska-ber.The enzyme catalyst may also be present as enzyme granules or granules (prill) which, together with the auxiliary materials, are filled into the capsule having the aforementioned solubility properties.
55
Det enzymkatalysatorholdige neutralisationsmiddel kan også formes til en overtrukket tablet, fra hvilken - med den forsinkede opløsning af overtrækket - først og fremmest hjælpematerialerne frigøres til ændring af pH-værdien af 10 hydrogenperoxidopløsningen, hvorpå enzymkatalysatoren frigøres ved en pH-værdi på ca. 7.The enzyme catalyst-containing neutralizing agent can also be formed into a coated tablet, from which - with the delayed solution of the coating - first of all, the auxiliary materials are released to change the pH of the hydrogen peroxide solution, whereupon the enzyme catalyst is released at a pH of approx. 7th
Egnet til det enzymkatalysatorholdige neutralisationsmiddel er endvidere en tolagstablet, hvor det ene lag, som indehol-15 der opløselige salte, tjener til at neutralisere hydrogenperoxidopløsningen, medens det andet lag indeholder enzymkatalysatoren, idet det er muligt at frigøre enten hjælpematerialerne eller enzymkatalysatoren først.Furthermore, suitable for the enzyme catalyst-containing neutralizing agent is a two-layered tablet, where one layer containing soluble salts serves to neutralize the hydrogen peroxide solution, while the other layer contains the enzyme catalyst, it being possible to release either the auxiliary materials or the enzyme catalyst first.
20 Neutralisationsmidlet kan også være til stede som en basisk gel i et overtræk, som er opløseligt ved en pH-værdi på 7. Enzymkatalysatoren kan også være til stede som en viskos opløsning af et overtræk, som omgiver hjælpematerialerne.The neutralizing agent may also be present as a basic gel in a coating which is soluble at a pH of 7. The enzyme catalyst may also be present as a viscous solution of a coating surrounding the auxiliary materials.
25 Endvidere kan neutralisationsmidlet have en semipermeabel membran som overtræk, gennem hvilket det vand, som skal opløse hjælpestofferne, trænger ind i det indre, og hvorfra de opløste salte når ydersiden på grund af det osmotiske tryk. Til dette formål kan den semipermeable membran have 30 en perforation, eller den kan ødelægges af det osmotiske tryk, hvorved hjælpematerialerne og enzymkatalysatoren frigøres. Enzymkatalysatoren kan være til stede som et indhyllet enzymprodukt.Furthermore, the neutralizing agent may have a semi-permeable membrane as a coating through which the water which is to dissolve the excipients enters the interior and from which the dissolved salts reach the outside due to the osmotic pressure. For this purpose, the semipermeable membrane may have a perforation, or it may be destroyed by the osmotic pressure, thereby releasing the auxiliary materials and enzyme catalyst. The enzyme catalyst may be present as a shrouded enzyme product.
35 Desuden er et tolagssystem med en opløselig og en semipermeabel membran egnet til forsinket frigivelse af hjælpema- 12 DK 166654 B1 terialerne og enzymkatalysatoren. Et uopløseligt membransystem kan udskiftes ved fornyet brug.In addition, a two-layer system with a soluble and a semi-permeable membrane is suitable for delayed release of the auxiliary materials and enzyme catalyst. An insoluble membrane system can be replaced by reuse.
Et passende tolagssystem kan konstrueres på en sådan måde, 5 at enzymkatalysatoren er omgivet af den semipermeable membran, på hvis yderside hjælpematerialerne findes. Et overtræk, som er opløseligt ved pH-værdien (mindre end 4) i den stabile hydrogenperoxidopløsning, omgiver endvidere hjælpematerialerne og den semipermeable membran, som omslutter 10 enzymkatalysatoren.An appropriate two-layer system can be constructed in such a way that the enzyme catalyst is surrounded by the semipermeable membrane on whose outer auxiliary materials are located. Furthermore, a coating which is soluble at the pH (less than 4) in the stable hydrogen peroxide solution surrounds the auxiliary materials and the semipermeable membrane enclosing the enzyme catalyst.
Sønderdelingen af hydrogenperoxidet kan påvises ved hjælp af en farveindikator. I denne forbindelse er det et spørgsmål om tilsætning af en pH/redoxindikator, som ikke trænger ind 15 i de bløde hydrofile kontaktlinser, og som er fysiologisk sikker. Farveindikatoren kan også være indrettet på en sådan måde, at den har en farve ved en pH-værdi på 7 i nærværelse af hydrogenperoxid og er farveløs ved en pH-værdi på 7 i fravær af hydrogenperoxid.The decomposition of the hydrogen peroxide can be detected by a color indicator. In this connection, it is a matter of adding a pH / redox indicator which does not penetrate into the soft hydrophilic contact lenses and is physiologically safe. The color indicator may also be arranged such that it has a color at a pH of 7 in the presence of hydrogen peroxide and is colorless at a pH of 7 in the absence of hydrogen peroxide.
2020
Den beholder, hvori kontaktlinsebehandlingen foretages, kan have ventilationsorganer i form af f.eks. en Bunsen-ventil, gennem hvilken det oxygen, som frigøres under neutralisationen og sønderdelingen af hydrogenperoxidet, kan undvige.The container in which the contact lens treatment is performed may have ventilation means in the form of e.g. a Bunsen valve through which the oxygen released during the neutralization and decomposition of the hydrogen peroxide can be avoided.
2525
Opfindelsen skal forklares nærmere i det følgende med henvisning til tegningen, hvor fig. 1-5 viser forskellige eksempler på systemer, som indeholder hydrogenperoxid og sønderdelingsenzymkata-30 lysator, fig. 6 viser tidsforløbet for behandlingen af en kontaktlinse med et eksempel på brugen af kontaktlinserensesættet, fig. 7 viser en behandlingsbeholder set fra siden, og fig. 8 viser et planbillede af en beholderdel, som kan skrues 35 ind i behandlingsbeholderen, og som indeholder par tikelformede bærestoffer, hvortil en hydrogenperoxid- 13 DK 166654 B1 sønderdelende enzymkatalysator er bundet.The invention will be explained in more detail below with reference to the drawing, in which 1-5 show various examples of systems containing hydrogen peroxide and decomposition enzyme catalyst; Figure 6 shows the time course of processing a contact lens with an example of the use of the contact lens cleaning kit; 7 is a side view of a treatment container; and FIG. Figure 8 shows a plan view of a container portion that can be screwed into the treatment container and containing particulate carriers to which a hydrogen peroxide decomposing enzyme catalyst is attached.
I det i fig. 1 viste eksempel er hjælpematerialer 1 og en hydrogenperoxidspaltende enzymkatalysator 2, f.eks. i form 5 af catalase, tilfældigt fordelt i et ydre hylster eller overtræk 3. Dette ydre overtræk 3 kan være vandopløseligt eller semipermeabelt, efter at det har været udsat for indvirkning i et vist tidsrum af hydrogenperoxidet, som har en steriliserende virkning på de kontaktlinser, som skal be-10 handles. Tykkelsen af overtrækket regulerer det tidsrum på indtil 4 timer, hvori hydrogenperoxidet virker på linserne, før der er frigivet en tilstrækkelig mængde catalase og hjælpematerialer ved opløsning af overtrækket 3 eller i kraft af semipermeabiliteten af dette overtræk, så at det 15 steriliserende hydrogenperoxid neutraliseres og elimineres ved enzymkatalytisk sønderdeling. I dette eksempel kan hjælpematerialerne og enzymkatalysatoren frigøres på samme tid.In the embodiment of FIG. 1, auxiliary materials 1 and a hydrogen peroxide cleaving enzyme catalyst 2, e.g. in the form 5 of catalase, randomly distributed in an outer casing or coating 3. This outer coating 3 may be water-soluble or semi-permeable after being subjected to action for a certain period of time by the hydrogen peroxide having a sterilizing effect on the contact lenses. to be treated. The thickness of the coating regulates the period of up to 4 hours during which the hydrogen peroxide acts on the lenses, before a sufficient amount of catalase and auxiliary materials are released by dissolving the coating 3 or by virtue of the semi-permeability of this coating to neutralize and eliminate the sterilizing hydrogen peroxide. by enzyme catalytic decomposition. In this example, the auxiliary materials and enzyme catalyst can be released at the same time.
I det i fig. 2 viste eksempel frigøres hjælpematerialerne 1 20 først, hvorved den steriliserende hydrogenperoxidopløsning neutraliseres. Derefter skal den hydrogenperoxidødelæggende enzymkatalysator 2, f.eks. i form af catalase, virke. Til dette formål forefindes et ydre hylster eller overtræk 3, som efter indvirkningen af hydrogenperoxidet i et vist tids-25 rum er opløseligt, eller som er tilstrækkeligt semipermeabelt, og som omgiver hjælpematerialerne 1. Hjælpematerialeme 1 omgiver enzymkatalysatoren 2, som atter er omgivet af et indre hylster eller overtræk 4, som også kan være opløseligt eller semipermeabelt.In the embodiment of FIG. 2, the auxiliary materials 1 20 are first released, thereby neutralizing the sterilizing hydrogen peroxide solution. Then the hydrogen peroxide-destroying enzyme catalyst 2, e.g. in the form of catalase, works. For this purpose, there is provided an outer casing or coating 3 which, after the action of the hydrogen peroxide, is soluble or sufficiently semipermeable and surrounds the auxiliary materials 1. The auxiliary materials 1 surround the enzyme catalyst 2, which is again surrounded by a inner sleeve or coating 4 which may also be soluble or semi-permeable.
30 I det i fig. 3 viste eksempel ligger enzymkatalysatoren 2 og hjælpematerialerne 1 ved siden af hinanden og er omgivet af et fælles ydre hylster eller overtræk, som er vandopløseligt eller semipermeabelt. I dette tilfælde kan hjælpematerialeme 35 1 og enzymkatalysatoren 2 være adskilt ved hjælp af en skil levæg 5.30 In the embodiment of FIG. 3, the enzyme catalyst 2 and the auxiliary materials 1 are adjacent to each other and are surrounded by a common outer casing or coating which is water-soluble or semi-permeable. In this case, the auxiliary materials 35 1 and the enzyme catalyst 2 can be separated by a separate living egg 5.
14 DK 166654 B1 1 det i fig. 4 viste eksempel frigøres enzymkatalysatoren 2, som kan være til stede i form af en viskos opløsning, først, hvorefter hjælpematerialerne 1 frigøres. Enzymkata- 5 lysatoren 2 er her omgivet af et ydre hylster eller overtræk 3, og hjælpematerialerne 1 er omgivet af et indre hylster eller overtræk 4. I denne udformning ligger hjælpematerialerne 1 inderst og er omgivet af enzymkatalysatoren 2.14 DK 166654 B1 shown in FIG. 4, the enzyme catalyst 2, which may be present in the form of a viscous solution, is first released, after which the auxiliary materials 1 are released. In this embodiment, the enzyme catalyst 2 is surrounded by an outer casing or coating 3, and the auxiliary materials 1 are surrounded by an inner casing or coating 4. In this embodiment, the auxiliary materials 1 are innermost and surrounded by the enzyme catalyst 2.
10 I det i fig. 5 viste eksempel foreligger enzymkatalysatoren 2 i form af små katalysatorkorn eller -prill, og hjælpematerialerne 1 er tilfældigt fordelt i det ydre hylster eller overtræk 3, som kan være opløseligt eller semipermeabelt.10 In the embodiment of FIG. 5, the enzyme catalyst 2 is in the form of small catalyst grains or prills, and the auxiliary materials 1 are randomly distributed in the outer casing or coating 3 which may be soluble or semi-permeable.
15 Fig. 6 er en grafisk fremstilling af tidsforløbet af behandlingen af kontaktlinserne med hydrogenperoxid og den efterfølgende ødelæggelse af hydrogenperoxidet, når det har virket i et ønsket tidsrum t]_. Det tidsrum, hvori hydrogenperoxidet virker, kan f.eks. fastlægges ved hjælp af tykkelsen af 20 overtrækket eller ved passende valg af overtræksmaterialet. Hydrogenperoxidindh'oldet er vist som ordinat, og det ses, at begyndelseskoncentrationen af hydrogenperoxid forbliver praktisk taget konstant indtil slutningen af tidsrummet for indvirkning t^. Efter frigørelse af hjælpemidlerne og/eller 25 enzymkatalysatoren falder hydrogenperoxidindholdet i behandlingsbeholderen hurtigt.FIG. 6 is a graphical representation of the time course of the treatment of the contact lenses with hydrogen peroxide and the subsequent destruction of the hydrogen peroxide when it has worked for a desired period of time. For example, the period of time during which the hydrogen peroxide works is determined by the thickness of the coating or by appropriate selection of the coating material. The hydrogen peroxide content is shown as ordinate, and it is seen that the initial concentration of hydrogen peroxide remains practically constant until the end of the period of action t ^. Upon release of the adjuvants and / or the enzyme catalyst, the hydrogen peroxide content of the treatment vessel drops rapidly.
Fig. 7 og 8 viser skematisk et eksempel på brugen af en behandlingsbeholder 1, hvori der i en forsænkning 4 i en 30 bunddel 2 er anbragt partikel formede bærestoffer 3, på hvilke en hydrogenperoxidnedbrydende enzymkatalysator er immobili-seret. Bunddelen 2 kan f.eks. være fastgjort ved hjælp af et gevind til behandlingsbeholderdelen 2 f.eks. som beskrevet i tysk offentliggørelsesskrift nr. 3.410.400. Bærestofferne 35 3, som er overtrukket med enzymkatalysatoren, er adskilt fra det indre 7 af beholderen ved hjælp af et indifferent 15 DK 166654 B1 sivæv 6, som er impermeabelt for den behandlingsopløsning, som findes i det indre 7 af beholderen. Farven af låget 8, som også er påskruet, og hvortil beholderne 9 for kontaktlinserne, som skal behandles, er fastgjort, som vist i tysk 5 offentliggørelsesskrift nr. 3.410.400, kan have en anden farve end farven af den påskruede bunddel 2, så at forveksling undgås.FIG. 7 and 8 show schematically an example of the use of a treatment container 1 in which a recess 4 in a bottom part 2 has particulate carriers 3 on which a hydrogen peroxide degrading enzyme catalyst is immobilized. The bottom part 2 can e.g. be secured by a thread to the treatment container part 2 e.g. as described in German Publication No. 3,410,400. The carriers 35 3 coated with the enzyme catalyst are separated from the inner 7 of the container by an inert tissue 6 which is impermeable to the treatment solution contained within the inner 7 of the container. The color of the lid 8, which is also screwed on, to which the containers 9 of the contact lenses to be treated are attached, as shown in German 5 Publication No. 3,410,400, may have a different color from the color of the screwed-on bottom part 2, so that confusion is avoided.
Claims (41)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19853532433 DE3532433A1 (en) | 1985-09-11 | 1985-09-11 | Contact-lens care set |
DE3532433 | 1985-09-11 |
Publications (3)
Publication Number | Publication Date |
---|---|
DK431286D0 DK431286D0 (en) | 1986-09-10 |
DK431286A DK431286A (en) | 1987-03-12 |
DK166654B1 true DK166654B1 (en) | 1993-06-28 |
Family
ID=6280690
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK431286A DK166654B1 (en) | 1985-09-11 | 1986-09-10 | THE CONTACT LENS CLEANING SITE WITH TWO TREATMENTS |
Country Status (6)
Country | Link |
---|---|
AU (1) | AU605464B2 (en) |
DE (1) | DE3532433A1 (en) |
DK (1) | DK166654B1 (en) |
ES (1) | ES2002483A6 (en) |
FI (1) | FI84521C (en) |
NO (1) | NO170308C (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4829001A (en) * | 1985-11-08 | 1989-05-09 | Minnesota Mining And Manufacturing Company | Enzymatic neutralization of hydrogen peroxide |
US4757014A (en) * | 1985-11-08 | 1988-07-12 | Minnesota Mining And Manufacturing Company | Immobilization of biologically active protein on a polymeric fibrous support |
JP2625697B2 (en) * | 1987-02-06 | 1997-07-02 | 三菱瓦斯化学株式会社 | Contact lens treatment method |
US5306352A (en) * | 1989-12-28 | 1994-04-26 | Ciba-Geigy Corporation | Peroxide disinfection method |
ES2020888A6 (en) * | 1990-06-11 | 1991-10-01 | Disop Sa | Method for preserving contact lenses in one step. |
DE19729831C2 (en) * | 1997-07-11 | 2000-07-27 | Albert Sturm | Contact lens care products |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3282702A (en) * | 1963-07-16 | 1966-11-01 | Union Carbide Corp | Process for removing hydrogen peroxide from liquids |
ATE30511T1 (en) * | 1981-12-21 | 1987-11-15 | Titmus Eurocon Kontaktlinsen | PROCEDURE FOR DISINFECTING AND CLEANING CONTACT LENSES. |
FR2544880B1 (en) * | 1983-04-20 | 1986-08-29 | Pos Lab | PROCESS FOR THE CLEANING AND DECONTAMINATION OF CONTACT LENSES AND COMPOSITION FOR ITS IMPLEMENTATION |
DE3329922A1 (en) * | 1983-08-19 | 1985-02-28 | Fa. Carl Zeiss, 7920 Heidenheim | CLEANING AND DISINFECTING SYSTEM FOR HARD AND SOFT CONTACT LENSES |
AU573247B2 (en) * | 1983-08-25 | 1988-06-02 | Advanced Medical Optics, Inc. | Contact lens disinfection |
-
1985
- 1985-09-11 DE DE19853532433 patent/DE3532433A1/en not_active Withdrawn
-
1986
- 1986-07-29 AU AU60652/86A patent/AU605464B2/en not_active Expired
- 1986-08-04 NO NO863126A patent/NO170308C/en not_active IP Right Cessation
- 1986-08-06 FI FI863207A patent/FI84521C/en not_active IP Right Cessation
- 1986-09-10 DK DK431286A patent/DK166654B1/en not_active IP Right Cessation
- 1986-09-11 ES ES8601791A patent/ES2002483A6/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
FI863207A0 (en) | 1986-08-06 |
DK431286A (en) | 1987-03-12 |
NO863126D0 (en) | 1986-08-04 |
AU605464B2 (en) | 1991-01-17 |
ES2002483A6 (en) | 1988-08-16 |
NO863126L (en) | 1987-03-12 |
AU6065286A (en) | 1987-03-12 |
FI84521B (en) | 1991-08-30 |
NO170308B (en) | 1992-06-22 |
FI863207A (en) | 1987-03-12 |
NO170308C (en) | 1992-09-30 |
DK431286D0 (en) | 1986-09-10 |
FI84521C (en) | 1992-07-07 |
DE3532433A1 (en) | 1987-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5011661A (en) | Contact lens care set | |
JP6568519B2 (en) | Medical covering device | |
JP5354502B2 (en) | Hydrogen peroxide delivery system | |
FI77575B (en) | STERILIZERINGBEHANDLING MED VAETESUPEROXID AV ARTIKLAR OCH NEUTRALISERING AV DENNAS RESTMAENGDER. | |
ES2343675T3 (en) | ANTIMICROBIAL MATERIALS STABILIZED AGAINST LIGHT. | |
US20150306064A1 (en) | Wound Care Products with Peracid Compositions | |
JPH10509052A (en) | Hydrogel patch | |
ES2753125T3 (en) | Wound care products with peracid compositions | |
DK166654B1 (en) | THE CONTACT LENS CLEANING SITE WITH TWO TREATMENTS | |
US20100062043A1 (en) | Methods, Systems and Devices for Administration of Chlorine Dioxide | |
US20060281165A1 (en) | Method for stabilization of enzymes during exposure to sterilizing radation | |
US11213604B2 (en) | Composition for dressing cutaneous lesions and manufacturing method thereof | |
JPS6263916A (en) | Contact lens mending agent | |
CA1297403C (en) | Contact-lens care set | |
JPH04506159A (en) | Composition | |
US5645848A (en) | Controlled release composition for active substances into an aqueous medium | |
CN109620842B (en) | Cross-linked polyvinylpyrrolidone and iodine complex, and preparation method and application thereof | |
CN108721328B (en) | Chitosan iodine biological material and preparation method thereof | |
JP3189131B2 (en) | How to clean and disinfect contact lenses | |
KR960002180B1 (en) | Oral osmotic system for metoprolol having a specific composition | |
RU2218185C2 (en) | Agent "delansal" for disinfecting and sterilization of medical-destination materials, tools, and equipment and a method for preparation thereof | |
RU2055583C1 (en) | Antiseptic agent | |
Deepalakshmi | Spectrophotometric Analysis and Evaluation of Sustained Release of 2% Chlorhexidine from a Polymeric Medium (PVA & PVA+ AgNPs) and Its Efficacy against E. Faecalis: An Invitro Study | |
SI8810221B (en) | Process for preparing of oral thepapeutic system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B1 | Patent granted (law 1993) | ||
PPF | Opposition filed | ||
PPF | Opposition filed | ||
PUG | Patent revoked |